SCHEMBL5578475

SCHEMBL5578475

O=C(Nc1c[nH]nc1-c1nc(CO)c(-c2ccc(N3CCOCC3)cc2)[nH]1)c1c(F)cccc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.42
BCL3 P20749 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
PDPK1 O15530 1/20 0.39
DGAT1 O75907 1/20 0.37
CCNE2 O96020 3/20 0.37
CDK4 P11802 3/20 0.37
CCND1 P24385 3/20 0.37
CCNE1 P24864 3/20 0.37
CDK2 P24941 3/20 0.37
EGFR P00533 2/20 0.37
ERBB2 P04626 2/20 0.37
IGF1R P08069 2/20 0.37
ROCK1 Q13464 2/20 0.36
KDM4E B2RXH2 1/20 0.36
TSHR P16473 1/20 0.36
HSD17B10 Q99714 1/20 0.36
AKT1 P31749 2/20 0.36
HDAC3 O15379 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5578195 0.87 PARP1 (0.42) PARP1BCL3NPC1RAB9APDPK1
SCHEMBL5578138 0.85 BCL3 (0.45) BCL3NPC1RAB9ACDK2ALDH1A1
SCHEMBL5578274 0.82 NPC1 (0.43) PARP1BCL3NPC1RAB9ADGAT1
SCHEMBL14511659 0.82 NPC1 (0.47) PARP1BCL3NPC1RAB9ADGAT1
SCHEMBL14511699 0.82 BCL3 (0.49) BCL3CDK2TSHRALDH1A1
SCHEMBL14511680 0.80 BCL3 (0.40) BCL3NPC1RAB9ACDK2TSHR
SCHEMBL5578149 0.79 CDK2 (0.39) CDK2EGFRROCK1FLT3MAP4K4
SCHEMBL5578102 0.77 MAPT (0.40) NPC1RAB9ACDK2EGFRROCK1
SCHEMBL5578093 0.76 BCL3 (0.47) BCL3NPC1RAB9ACDK2KDM4E
SCHEMBL12253042 0.75 NPC1 (0.42) PARP1BCL3NPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070105900-A1 Pharmaceutical compounds ATEX THERAPEUTICS, LIMITED (GB) 2007-05-10 US disclosed
US-20070105900-A1 Pharmaceutical compounds ATEX THERAPEUTICS, LIMITED (GB) 2007-05-10 US disclosed
US-20070105900-A1 Pharmaceutical compounds ATEX THERAPEUTICS, LIMITED (GB) 2007-05-10 US disclosed
EP-1648449-A2 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS Astex Therapeutics Limited (GB) 2006-04-26 EP disclosed
WO-2005002576-A2 IMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2005-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105900-A1 Pharmaceutical compounds AURKA, AURKC, CDK1 PARP1 619/4885BCL3 2401/4885NPC1 1220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.